Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$40.25 - $52.99 $520,432 - $685,160
-12,930 Reduced 70.77%
5,341 $221,000
Q1 2024

Apr 18, 2024

BUY
$47.98 - $54.4 $218,213 - $247,411
4,548 Added 33.14%
18,271 $990,000
Q4 2023

Feb 05, 2024

SELL
$48.48 - $57.85 $71,508 - $85,328
-1,475 Reduced 9.71%
13,723 $704,000
Q3 2023

Oct 30, 2023

BUY
$57.89 - $64.73 $81,856 - $91,528
1,414 Added 10.26%
15,198 $882,000
Q2 2023

Jul 18, 2023

BUY
$63.71 - $70.74 $76,643 - $85,100
1,203 Added 9.56%
13,784 $881,000
Q1 2023

May 04, 2023

SELL
$65.71 - $74.53 $1,971 - $2,235
-30 Reduced 0.24%
12,581 $871,000
Q4 2022

Feb 13, 2023

BUY
$68.48 - $81.09 $151,135 - $178,965
2,207 Added 21.21%
12,611 $907,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $123 - $73,228
953 Added 10.08%
10,404 $740,000
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $26,942 - $29,672
-371 Reduced 3.78%
9,451 $728,000
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $100,396 - $120,384
-1,633 Reduced 14.26%
9,822 $717,000
Q4 2021

Feb 15, 2022

SELL
$53.63 - $62.52 $16,732 - $19,506
-312 Reduced 2.65%
11,455 $714,000
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $137,984 - $161,630
2,332 Added 24.72%
11,767 $696,000
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $584,120 - $636,107
9,435 New
9,435 $630,000
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $450,509 - $506,690
-7,592 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $203,187 - $230,248
3,519 Added 86.4%
7,592 $470,000
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $223,281 - $261,038
4,073 New
4,073 $239,000
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $56,265 - $62,217
-1,261 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $56,896 - $67,841
1,261 New
1,261 $60,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $126B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Little House Capital LLC Portfolio

Follow Little House Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Little House Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Little House Capital LLC with notifications on news.